PROCESS FOR PREPARING APOLIPOPROTEIN A-I (APO A-I)

(19)

(11)

EP 4 209 504 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 A1)

(48)	Corrigendum issued on:
	14.02.2024 Bulletin 2024/07

(43)	Date of publication:
	12.07.2023 Bulletin 2023/28

(21)	Application number: 22213998.2

(22)	Date of filing: 05.06.2014

(51)

International Patent Classification (IPC):

C07K 14/775^(2006.01)
C07K 1/30^(2006.01)
C07K 1/36^(2006.01)
A61K 31/685^(2006.01)
A61P 3/06^(2006.01)

C07K 1/14^(2006.01)
C07K 1/34^(2006.01)
A61K 38/17^(2006.01)
A61K 31/688^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 38/17; A61K 38/00; C07K 14/775; A61P 1/16; A61P 29/00; A61P 3/06; A61P 39/02; A61P 9/10

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

05.06.2013 US 201361831304 P

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	14808213.4 / 3004160

(71)	Applicant: CSL Limited
	Melbourne VIC 3000 (AU)

(72)	Inventors:
	VUCICA, Yvonne 3006 Bern (CH) WARREN, Gary, Lee Bourbonnais, IL 60944 (US)

(74)	Representative: Carpmaels & Ransford LLP
	One Southampton Row London WC1B 5HA London WC1B 5HA (GB)


	Remarks:
	This application was filed on 15-12-2022 as a divisional application to the application mentioned under INID code 62.


	Remarks:
	Claims filed after the date of filing of the application / after the date of receipt of the divisional application (Rule 68(4) EPC).

(54)	PROCESS FOR PREPARING APOLIPOPROTEIN A-I (APO A-I)

(57) The present invention relates to processes of obtaining Apo A-I from an Apo A-I containing protein fraction (A), comprising suspending the Apo A-I containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-I proteins solubilized, followed by precipitating Apo A-I from the suspension and collecting the Apo A-I precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-I, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.